Several new treatments are transforming glucose care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide standing out leading options. Retatrutide, a double GIP and GLP-1 target agonist, shows substantial fat reduction and enhanced blood sugar levels. Cagrillintide, another GLP-1 stimulant, is currently in clinical trials, suggesting pos